EPCORE NHL-1 (NCT03625037) was the first-in-human phase I/II trial exploring the dose escalation and dose expansion of subcutaneous epcoritamab in R/R CD20-positive NHL previously treated with an anti-CD20 mAb. This evidence concerns the gene MS4A1 and non-Hodgkin lymphoma.